ARV-102
Parkinson's Disease
Phase 1Active - >50% LRRK2 degradation in CSF reported
Key Facts
Indication
Parkinson's Disease
Phase
Phase 1
Status
Active - >50% LRRK2 degradation in CSF reported
Company
About Arvinas
Arvinas is a leader in the field of targeted protein degradation, founded on groundbreaking research from Yale University. The company's PROTAC® platform enables the development of therapeutics that harness the body's natural protein disposal system to degrade disease-causing proteins, potentially addressing previously 'undruggable' targets. With multiple clinical-stage assets, strategic partnerships, and a robust discovery engine, Arvinas aims to revolutionize treatment for serious diseases in oncology and neurology.
View full company profileOther Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ABBV-951 | AbbVie | Phase 3 |
| UCB0107 | UCB | Phase 1 |
| Stalevo | Orion Corporation | Approved |
| Comtan/Comtess | Orion Corporation | Approved |
| CHRONOS-PD Platform | Grifols | Research |
| GT-001 (Gene Therapy) | Sumitomo Pharma | Phase 1/2 |
| CREXONT (Carbidopa/Levodopa) | Amneal Pharmaceuticals | Approved |
| BIIB122/DNL151 | Denali Therapeutics | Phase 3 |
| ABBV-0805 | BioArctic AB | Phase 1 |
| BAN1202 | BioArctic AB | Preclinical |
| AAV-GAD | MeiraGTx | Preclinical/Phase 1 |
| Not Specified | Minerva Neurosciences | Clinical Stage |